Mohammad Azab
YOU?
Author Swipe
View article: Leveraging Artificial Intelligence in the Diagnosis and Management of Diabetic Foot Ulcers: A Review of Current Trends and Future Directions"
Leveraging Artificial Intelligence in the Diagnosis and Management of Diabetic Foot Ulcers: A Review of Current Trends and Future Directions" Open
View article: Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial Open
Guadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed/refractory acute myeloid leukemia (AML) were randomly assigned to guadecitabine or a preselected treatment choice (…
View article: Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients Open
View article: P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY Open
Background: The genomic landscape of acute myeloid leukemia (AML) has been previously mostly studied in younger patients who received intensive chemotherapy. Data in older patients receiving less intensive therapies are scarce. In addition…
View article: TOXICOLOGICAL AND BIOCHEMICAL EFFECTS OF CALOTROPIS PROCERA LEAF EXTRACTS ON THE COTTON LEAF WORM, SPODOPTERA LITTORALIS (BOIS).
TOXICOLOGICAL AND BIOCHEMICAL EFFECTS OF CALOTROPIS PROCERA LEAF EXTRACTS ON THE COTTON LEAF WORM, SPODOPTERA LITTORALIS (BOIS). Open
In a trial to explore new alternatives to chemical insecticides whose negative side effects on humans and the environment are a serious concern, natural alternatives are being addressed to discover new, cost-effective, and environmentally …
View article: Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer Open
Purpose:Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadec…
View article: Supplmentary Methods, Tables 1 - 6, Figure Legends from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Supplmentary Methods, Tables 1 - 6, Figure Legends from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Open
Supplementary methods Supplementary Tables S1-S6 Supplementary Figure legends for SF1-SF11 Supplementary Table S1. Primers used for qRT-PCR Supplementary Table S2. Primers used for pyrosequencing Supplementary Table S3. IC50 values for CDD…
View article: Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer Open
Supplementary Figure S1 and supplementary tables
View article: Supplmentary Methods, Tables 1 - 6, Figure Legends from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Supplmentary Methods, Tables 1 - 6, Figure Legends from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Open
Supplementary methods Supplementary Tables S1-S6 Supplementary Figure legends for SF1-SF11 Supplementary Table S1. Primers used for qRT-PCR Supplementary Table S2. Primers used for pyrosequencing Supplementary Table S3. IC50 values for CDD…
View article: Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer Open
Supplementary methods
View article: Data from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Data from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Open
Purpose: To investigate SGI-110 as a “chemosensitizer” in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer.Experimenta…
View article: Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer Open
Purpose:Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadec…
View article: Data from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Data from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Open
Purpose: To investigate SGI-110 as a “chemosensitizer” in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer.Experimenta…
View article: Data from A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Data from A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses Open
Purpose: Epigenetic changes are implicated in acquired resistance to platinum. Guadecitabine is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, along with pharmacokinetic (PK) and pharmacodynamic…
View article: Data from A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Data from A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses Open
Purpose: Epigenetic changes are implicated in acquired resistance to platinum. Guadecitabine is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, along with pharmacokinetic (PK) and pharmacodynamic…
View article: Supplementary Figures S1-S11 from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Supplementary Figures S1-S11 from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Open
Supplementary Figure S1. Diagrams of biweekly and QD5 drug (SGI-110 and CDDP) treatment schedules for mice. (A). For non-tumor bearing mice study, mice (3 per group) were injected with different doses of SGI-110 (2 mg/kg, 5 mg/kg, s.c.), C…
View article: Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer Open
Supplementary Figure S1 and supplementary tables
View article: Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer Open
Supplementary methods
View article: Supplementary Figures S1-S11 from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Supplementary Figures S1-S11 from The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Open
Supplementary Figure S1. Diagrams of biweekly and QD5 drug (SGI-110 and CDDP) treatment schedules for mice. (A). For non-tumor bearing mice study, mice (3 per group) were injected with different doses of SGI-110 (2 mg/kg, 5 mg/kg, s.c.), C…
View article: Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy Open
View article: A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation Open
View article: Understanding the factors influencing healthcare providers’ burnout during the outbreak of COVID-19 in Jordanian hospitals
Understanding the factors influencing healthcare providers’ burnout during the outbreak of COVID-19 in Jordanian hospitals Open
Background Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. The nature of healthcare providers’ occupation puts them at an increased risk of getting any contagious disease, including COVID-1…
View article: A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer Open
Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guade…
View article: Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial Open
Purpose: The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness of cancer immunotherapies. The phase Ib NIBIT-M4 trial tested this hypothesis using the next-generation DHA guadecitabi…
View article: Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia Open
View article: Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial Open
View article: Additional file 6: of Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Additional file 6: of Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia Open
Table S6. Canonical pathway analysis (Ingenuity Pathway Analysis) of 121 genes with differentially methylated promoters from an analysis of 17,793 CpG sites (â Ľâ 20 reads). (XLSX 8 kb)
View article: Additional file 7: of Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Additional file 7: of Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia Open
Table S7. Comparison of the major 19 mutated genes in this study and TCGA tn-AML (n = 200). (p
View article: Plasma and saliva levels of three metals in waterpipe smokers: a case control study
Plasma and saliva levels of three metals in waterpipe smokers: a case control study Open
In this case-control study, the influence of waterpipe tobacco smoking on the plasma and saliva levels of cadmium, lead and zinc was examined in participants who were waterpipe tobacco smokers (WS) or never-smokers (NS). The concentration …
View article: A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses Open
Purpose: Epigenetic changes are implicated in acquired resistance to platinum. Guadecitabine is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, along with pharmacokinetic (PK) and pharmacodynamic analys…